Salirasib

Drug Profile

Salirasib

Alternative Names: KD 032; ONO-7056; S-Farnesylthiosalicyclic acid; Transfarnesylthiosalicyclic acid

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Concordia Pharmaceuticals
  • Developer Concordia Pharmaceuticals; Johns Hopkins University; Kadmon Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Ono Pharmaceutical
  • Class Antineoplastics; Benzoic acids; Sulfides
  • Mechanism of Action MTOR protein inhibitors; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 31 Oct 2015 Discontinued - Phase-I for Solid tumours in Japan (PO)
  • 15 Jun 2015 Discontinued - Phase-I for Colorectal cancer in USA (PO)
  • 15 Jun 2015 Discontinued - Phase-I/II for Pancreatic cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top